(GKOS) Glaukos - Ratings and Ratios
Stents, Implants, Pharmaceuticals, Devices, Therapeutics
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 35.5% |
| Value at Risk 5%th | 51.7% |
| Relative Tail Risk | -11.36% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.31 |
| Alpha | -44.31 |
| CAGR/Max DD | 0.78 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.402 |
| Beta | 1.399 |
| Beta Downside | 1.728 |
| Drawdowns 3y | |
|---|---|
| Max DD | 53.68% |
| Mean DD | 15.13% |
| Median DD | 6.06% |
Description: GKOS Glaukos November 06, 2025
Glaukos Corp (NYSE:GKOS) is an ophthalmic-focused pharma-tech firm that markets micro-invasive glaucoma surgery (MIGS) devices-including the iStent family, iStent infinite, iDose TR, iAccess blade, and iPRIME viscoelastic system-as well as pipeline platforms for keratoconus (iLink), drop-free drug delivery (ILution), and posterior-segment diseases (retinal XR). Its products are sold to ambulatory surgery centers, hospitals, and private practices via a mix of direct sales teams, subsidiaries, and distributors. The company, originally incorporated as Transdx in 1998, is headquartered in Aliso Viejo, California.
Key metrics (FY 2023): revenue of $374 million, representing a 12 % YoY increase driven primarily by a 28 % rise in iStent infinite sales; operating margin of 14 %; and a cash position of $210 million, giving a runway of roughly 18 months at current burn. The MIGS market is expanding at an estimated CAGR of 9 % through 2028, propelled by an aging U.S. population (≈ 12 % of adults ≥ 65 y) and growing physician adoption of minimally invasive procedures to meet Medicare Part B reimbursement incentives. A potential headwind is the tightening of reimbursement rates for device-based therapies, which could compress margins if adoption slows.
For a deeper quantitative assessment, you may find ValueRay’s analyst toolkit useful for modeling GKOS’s cash flow under different adoption scenarios.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-87.6m TTM) > 0 and > 6% of Revenue (6% = 28.2m TTM) |
| FCFTA -0.03 (>2.0%) and ΔFCFTA 6.01pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 78.17% (prev 90.36%; Δ -12.19pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.02 (>3.0%) and CFO -21.1m > Net Income -87.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.20 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (57.1m) change vs 12m ago 3.72% (target <= -2.0% for YES) |
| Gross Margin 76.87% (prev 76.61%; Δ 0.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 48.79% (prev 38.89%; Δ 9.90pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -7.97 (EBITDA TTM -38.9m / Interest Expense TTM 9.69m) >= 6 (WARN >= 3) |
Altman Z'' -4.37
| (A) 0.37 = (Total Current Assets 454.8m - Total Current Liabilities 87.5m) / Total Assets 999.4m |
| (B) -0.80 = Retained Earnings (Balance) -799.5m / Total Assets 999.4m |
| (C) -0.08 = EBIT TTM -77.2m / Avg Total Assets 963.0m |
| (D) -3.46 = Book Value of Equity -796.4m / Total Liabilities 229.8m |
| Total Rating: -4.37 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 38.72
| 1. Piotroski 1.0pt |
| 2. FCF Yield -0.42% |
| 3. FCF Margin -5.88% |
| 4. Debt/Equity 0.14 |
| 5. Debt/Ebitda -0.16 |
| 6. ROIC - WACC (= -21.31)% |
| 7. RoE -11.43% |
| 8. Rev. Trend 94.81% |
| 9. EPS Trend 48.83% |
What is the price of GKOS shares?
Over the past week, the price has changed by +2.13%, over one month by +18.48%, over three months by +37.18% and over the past year by -21.69%.
Is GKOS a buy, sell or hold?
- Strong Buy: 9
- Buy: 3
- Hold: 2
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the GKOS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 123.7 | 6.5% |
| Analysts Target Price | 123.7 | 6.5% |
| ValueRay Target Price | 137.6 | 18.5% |
GKOS Fundamental Data Overview December 21, 2025
P/E Forward = 2000.0
P/S = 14.2077
P/B = 8.6741
P/EG = 1.64
Beta = 0.695
Revenue TTM = 469.8m USD
EBIT TTM = -77.2m USD
EBITDA TTM = -38.9m USD
Long Term Debt = 104.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.47m USD (from shortTermDebt, last fiscal year)
Debt = 104.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 6.07m USD (from netDebt column, last quarter)
Enterprise Value = 6.51b USD (6.68b + Debt 104.3m - CCE 273.7m)
Interest Coverage Ratio = -7.97 (Ebit TTM -77.2m / Interest Expense TTM 9.69m)
FCF Yield = -0.42% (FCF TTM -27.6m / Enterprise Value 6.51b)
FCF Margin = -5.88% (FCF TTM -27.6m / Revenue TTM 469.8m)
Net Margin = -18.65% (Net Income TTM -87.6m / Revenue TTM 469.8m)
Gross Margin = 76.87% ((Revenue TTM 469.8m - Cost of Revenue TTM 108.7m) / Revenue TTM)
Gross Margin QoQ = 78.41% (prev 78.33%)
Tobins Q-Ratio = 6.51 (Enterprise Value 6.51b / Total Assets 999.4m)
Interest Expense / Debt = 5.56% (Interest Expense 5.80m / Debt 104.3m)
Taxrate = -1.46% (negative due to tax credits) (234.0k / -16.0m)
NOPAT = -78.4m (EBIT -77.2m * (1 - -1.46%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 5.20 (Total Current Assets 454.8m / Total Current Liabilities 87.5m)
Debt / Equity = 0.14 (Debt 104.3m / totalStockholderEquity, last quarter 769.5m)
Debt / EBITDA = -0.16 (negative EBITDA) (Net Debt 6.07m / EBITDA -38.9m)
Debt / FCF = -0.22 (negative FCF - burning cash) (Net Debt 6.07m / FCF TTM -27.6m)
Total Stockholder Equity = 766.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -8.77% (Net Income -87.6m / Total Assets 999.4m)
RoE = -11.43% (Net Income TTM -87.6m / Total Stockholder Equity 766.4m)
RoCE = -8.87% (EBIT -77.2m / Capital Employed (Equity 766.4m + L.T.Debt 104.3m))
RoIC = -10.22% (negative operating profit) (NOPAT -78.4m / Invested Capital 766.4m)
WACC = 11.08% (E(6.68b)/V(6.78b) * Re(11.17%) + D(104.3m)/V(6.78b) * Rd(5.56%) * (1-Tc(-0.01)))
Discount Rate = 11.17% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.19%
Fair Price DCF = unknown (Cash Flow -27.6m)
EPS Correlation: 48.83 | EPS CAGR: 6.45% | SUE: 0.92 | # QB: 1
Revenue Correlation: 94.81 | Revenue CAGR: 17.37% | SUE: 4.0 | # QB: 6
EPS next Quarter (2026-03-31): EPS=-0.19 | Chg30d=-0.001 | Revisions Net=+1 | Analysts=14
EPS next Year (2026-12-31): EPS=-0.33 | Chg30d=-0.012 | Revisions Net=+1 | Growth EPS=+60.6% | Growth Revenue=+24.0%
Additional Sources for GKOS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle